

REMARKS

Claims 1-6, 8, and 21 are pending after entry of this amendment. Claims 7, and 9-20 have been canceled without prejudice. Applicants reserve the right to prosecute the subject matter in related applications. Claim 21 has been added, and claims 1-6, and 8 have been amended to more particularly point out and distinctly claim that which Applicants regard as the invention. The amendments in claims 1-6, and 8 are fully supported by the specification, *inter alia*, on page 5, lines 6-18; page 11, line 19 to page 13, line 3; page 14, lines 20-27; page 20, lines 15-22.

CONCLUSION

Applicants respectfully request that the above-made remarks and amendments be entered and made of record in the file history of the instant application. An early allowance of the application is earnestly requested.

Respectfully submitted,

Date October 9, 2001

By: Laura A. Coruzzi ^{40,258}
Laura A. Coruzzi 30,742
PENNIE & EDMONDS (Reg. No.)
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

EXHIBIT A**VERSION WITH MARKINGS TO SHOW CHANGES MADE****U.S. Patent Application Serial No. 09/602,833**

1. (Amended) An isolated nucleic acid molecule comprising at least 24 contiguous bases of [a nucleotide sequence first disclosed in one of the *SGT4* genes described in the group consisting of] SEQ ID [NOS:1 and] NO:1 or 3, or the complement thereof.
2. (Amended) An isolated nucleic acid molecule comprising a nucleotide sequence that (i) consists of the nucleotide sequence of SEQ ID NO:1 or 3, or (ii) encodes [an] the amino acid sequence [selected from the group consisting] of SEQ ID [NOS:2 and] NO:2 or 4 ;or the complement thereof.
3. (Amended) An isolated nucleic acid molecule [which] that hybridizes under stringent conditions to [the] a second nucleic acid molecule [according to any one of Claims 1-2] consisting of: (a) the nucleic acid sequence of SEQ ID NO:1 or 3; or (b) a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO:2 or 4, wherein the stringent conditions comprise hybridization in 6xSSC, 50mM Tris HCl (pH 7.5), 1mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500µg/ml denatured salmon sperm DNA at 65°C, and washing in 0.1x SSC at 50°C, or the complement thereof.
4. (Amended) A recombinant vector comprising the nucleic acid molecule [according to] of Claim 1, 2 or 3.
5. (Amended) An expression vector comprising the nucleic acid molecule [according to] of Claim 1, 2 or 3 operatively associated with a regulatory nucleic acid [controlling] that controls the expression of the nucleic acid molecule in a host cell.
6. (Amended) A [genetically engineered] host cell comprising the [nucleic acid molecule according to Claim 3] vector of Claim 4.
8. (Amended) A method for producing a polypeptide comprising introducing into [expressing a nucleic acid molecule according to Claim 3 in] a cell an expression vector

comprising the nucleic acid molecule of Claim 1, 2, or 3 operatively associated with a regulatory nucleic acid that controls the expression of the nucleic acid molecule in a host cell; and culturing the cell such that the polypeptide encoded by the nucleic acid molecule is produced.

21. (New) A host cell genetically engineered to express the nucleic acid molecule of Claim 1, 2, or 3 operatively associated with a regulatory nucleic acid controlling the expression of the nucleic acid molecule in the host cell.